{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone%C2%AE+%28IM%29", "query": { "intervention": "Fluzone® (IM)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 39, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fluzone%C2%AE+%28IM%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-16T14:26:15.023Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04969276", "title": "Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza Immunization", "Healthy Volunteers" ], "interventions": [ { "name": "Quadrivalent Inactivated Influenza High Dose", "type": "BIOLOGICAL" }, { "name": "COVID-19 mRNA Vaccine (nucleoside modified)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 306, "start_date": "2021-07-16", "completion_date": "2022-02-08", "has_results": true, "last_update_posted_date": "2025-09-12", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 6, "location_summary": "Glendale, Arizona • San Diego, California • Vista, California + 3 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Vista", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Peoria", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04969276" }, { "nct_id": "NCT02563093", "title": "Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative", "type": "BIOLOGICAL" }, { "name": "Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation", "type": "BIOLOGICAL" }, { "name": "Fluzone High-Dose vaccine, 2015-2016 formulation", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2015-09", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2016-12-12", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 4, "location_summary": "Santa Rosa, California • Council Bluffs, Iowa • Metairie, Louisiana + 1 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Council Bluffs", "state": "Iowa" }, { "city": "Metairie", "state": "Louisiana" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02563093" }, { "nct_id": "NCT01181323", "title": "Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Cold-adapted live attenuated influenza virus vaccine, trivalent", "type": "BIOLOGICAL" }, { "name": "Trivalent inactivated influenza vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 240, "start_date": "2011-09", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-01-28", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • St Louis, Missouri + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01181323" }, { "nct_id": "NCT01011049", "title": "Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Influenza Virus Vaccine USP Trivalent Types A and B", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 1250, "start_date": "2009-09", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2016-04-14", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 44, "location_summary": "Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 38 more", "locations": [ { "city": "Hoover", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01011049" }, { "nct_id": "NCT02141581", "title": "Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Fluzone® (IM)", "type": "BIOLOGICAL" }, { "name": "Fluzone® Intradermal (ID)", "type": "BIOLOGICAL" }, { "name": "2011-2012 FluMist®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "8 Years", "maximum_age": "34 Years", "sex": "ALL", "summary": "8 Years to 34 Years" }, "enrollment_count": 86, "start_date": "2011-08", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-05-07", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02141581" }, { "nct_id": "NCT03312699", "title": "Effects of Aging on Primary and Secondary Vaccine Responses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza", "Hepatitis A", "Typhoid", "Healthy Adults" ], "interventions": [ { "name": "Fluzone® quadrivalent", "type": "BIOLOGICAL" }, { "name": "Fluzone High Dose", "type": "BIOLOGICAL" }, { "name": "Fluad", "type": "BIOLOGICAL" }, { "name": "Vaqta", "type": "BIOLOGICAL" }, { "name": "Typhim Vi", "type": "BIOLOGICAL" }, { "name": "Vivotif", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2017-09-19", "completion_date": "2023-12-31", "has_results": false, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03312699" }, { "nct_id": "NCT00253734", "title": "Immunogenicity and Safety of Different Doses of Fluzone® Influenza", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "Fluzone® (IM)", "type": "BIOLOGICAL" }, { "name": "Fluzone®", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 217, "start_date": "2005-11", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-06-03", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253734" }, { "nct_id": "NCT02918006", "title": "A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "VXA-A1.1", "type": "BIOLOGICAL" }, { "name": "Fluzone®", "type": "BIOLOGICAL" }, { "name": "Placebo Tablets", "type": "OTHER" }, { "name": "Saline Solution for Placebo IM Injection", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Vaxart", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 179, "start_date": "2016-08-31", "completion_date": "2018-01-19", "has_results": true, "last_update_posted_date": "2022-10-06", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 1, "location_summary": "Costa Mesa, California", "locations": [ { "city": "Costa Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02918006" }, { "nct_id": "NCT03283319", "title": "Panblok H7 Vaccine Adjuvanted With AS03 or MF59", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "3.75 ug Panblok H7", "type": "BIOLOGICAL" }, { "name": "7.5 ug Panblok H7", "type": "BIOLOGICAL" }, { "name": "15 ug Panblok H7", "type": "BIOLOGICAL" }, { "name": "MF59", "type": "BIOLOGICAL" }, { "name": "AS03", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Biomedical Advanced Research and Development Authority", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 366, "start_date": "2017-09-20", "completion_date": "2018-11-09", "has_results": true, "last_update_posted_date": "2020-05-06", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 4, "location_summary": "Lenexa, Kansas • Wichita, Kansas • Lexington, Kentucky + 1 more", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03283319" }, { "nct_id": "NCT05397223", "title": "A Study of Modified mRNA Vaccines in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "SARS-CoV-2", "Seasonal Influenza", "Respiratory Syncytial Virus", "Cytomegalovirus" ], "interventions": [ { "name": "mRNA-1273", "type": "BIOLOGICAL" }, { "name": "mRNA-1010", "type": "BIOLOGICAL" }, { "name": "mRNA-1345", "type": "BIOLOGICAL" }, { "name": "FLUAD®", "type": "BIOLOGICAL" }, { "name": "mRNA-1647", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 308, "start_date": "2022-05-24", "completion_date": "2026-02-27", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-09-16T14:26:15.023Z", "location_count": 8, "location_summary": "Hollywood, Florida • Savannah, Georgia • Sioux City, Iowa + 4 more", "locations": [ { "city": "Hollywood", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05397223" } ] }